Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma

Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma

Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been descri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Chen, Lei Zhuang, Danhong Zhang, Xianghui Du, Liming Sheng
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2022/4015897
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
by: Ming Zhang, et al.
Published: (2022-03-01)

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial
by: Tengfei Zhang, et al.
Published: (2025-07-01)

Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Published: (2022-06-01)

Use of camrelizumab in treatment of nasopharyngeal carcinoma
by: Yu. V. Alymov, et al.
Published: (2024-12-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma
by: Kazuhiro Shiraishi, et al.
Published: (2025-03-01)

Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment
by: Bi Sheng MD, et al.
Published: (2025-01-01)

Role of Oral and Esophageal Microbiota in Esophageal Squamous Cell Carcinoma
by: Kong Jinyu, et al.
Published: (2025-07-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
by: Xiang Han, et al.
Published: (2025-12-01)

Whole genome sequencing revealed esophageal squamous cell carcinoma related biomarkers
by: Mingjun Li, et al.
Published: (2025-01-01)

Whole genome sequencing revealed esophageal squamous cell carcinoma related biomarkers.
by: Mingjun Li, et al.
Published: (2025-01-01)

Cutaneous metastasis in esophageal squamous cell carcinoma
by: Rajiv Baijal, et al.
Published: (2013-01-01)

Esophageal Papillomatosis Complicated by Squamous Cell Carcinoma
by: Tan Attila, et al.
Published: (2009-01-01)

Esophageal squamous cell carcinoma and prognosis in Taiwan
by: Ya‐Fu Cheng, et al.
Published: (2018-09-01)

Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma
by: Siyou Deng, et al.
Published: (2025-06-01)

Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province
by: Xiaoyang DUAN, et al.
Published: (2025-02-01)

Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids
by: Suya Shen, et al.
Published: (2024-12-01)

The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma
by: Danjing Luo, et al.
Published: (2024-12-01)

The Mural Form of Eosinophilic Esophagitis Is Accompanied by Superficial Esophageal Squamous Cell Carcinoma
by: Zhao Jingsheng, et al.
Published: (2012-01-01)

promoter methylation is associated with prognosis in esophageal squamous cell carcinoma
by: Xiaoying Chen, et al.
Published: (2017-02-01)

SKA1/2/3 is a prognostic and predictive biomarker in esophageal adenocarcinoma and squamous cell carcinoma
by: Liming Zhang, et al.
Published: (2024-11-01)

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
by: Baiguo Xu, et al.
Published: (2025-06-01)

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
by: Xuesong Li, et al.
Published: (2025-03-01)

Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma
by: Likun Liu, et al.
Published: (2025-08-01)

Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review
by: Yan Lin, et al.
Published: (2025-07-01)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
by: Ting Zhang, et al.
Published: (2025-03-01)

Expression and correlation of Surfeit 4 gene in esophageal squamous cell carcinoma
by: Jun-xing Liu, et al.
Published: (2024-12-01)

Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma
by: Qing Liu, et al.
Published: (2024-08-01)

The Utility of Immunohistochemistry in Differentiating Metastatic Primary Squamous Cell Carcinoma of the Thyroid from a Primary Lung Squamous Cell Carcinoma
by: Nern Hoong Kao, et al.
Published: (2019-01-01)

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma
by: Qi Wang, et al.
Published: (2025-07-01)

Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma
by: Lauren Podger, et al.
Published: (2025-05-01)

CT-radiomics combined with inflammatory indicators for prediction of progression free survival of resectable esophageal squamous cell carcinoma
by: Yating Wang, et al.
Published: (2025-05-01)

The genomic landscape of esophageal squamous cell carcinoma cell lines
by: Chao Zhang, et al.
Published: (2025-05-01)

Esophageal Squamous Cell Carcinoma Presenting as a Subepithelial Tumor
by: Soon Young Kim, et al.
Published: (2017-09-01)

Characteristics of Esophageal Squamous Cell Carcinomas Based on Circumferential Localization
by: Natsuki Ishida, et al.
Published: (2024-12-01)